Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm

作者：Dubis Joanna^*; Zuk Natalia; Grendziak Ryszard; Zapotoczny Norbert; Pfanhauser Monika; Witkiewicz Wojciech

来源：Blood Coagulation & Fibrinolysis, 2014, 25(3): 226-231.

DOI：10.1097/MBC.0000000000000028

• abdominal aortic aneurysm
• fibrinolysis
• thrombin activatable fibrinolysis inhibitor

Patients with abdominal aortic aneurysm (AAA) experience impaired balance between fibrinolysis and coagulation, manifested by increased prothrombotic tendency and intensified inflammatory processes. The aim of this study was to evaluate the TAFI activity level (thrombin activatable fibrinolysis inhibitor) in the plasma of AAA patients. Plasma levels of PAI-1 (plasminogen activator inhibitor type 1), urokinase-type plasminogen activator and uPAR (urokinase-type plasminogen activator receptor) were measured as markers of fibrinolytic activity. The study showed that the activity of the thrombin-activatable fibrinolysis inhibitor in the plasma of AAA patients was significantly lower than in the plasma of the control individuals (64.6 +/- 10.1 vs. 54.2 +/- 10.9%, P < 0.0001). TAFI activity positively correlated with the white blood cell count (r = 0.486, P < 0.005). The uPAR concentration in the AAA patients was statistically significantly higher than in the control group and positively correlated with TAFI activity (r = 0.409, P = 0.02). The levels of PAI-1 and D-dimers (fibrin fragments) were significantly higher in patients with AAA than in the control group (44.3 +/- 17.5 vs. 21.7 +/- 8.7 ng/ml and 1869.6 +/- 1490.1 vs. 181.5 +/- 188.6 ng/ml, respectively). Lowered activity of the fibrinolysis inhibitor TAFI may heighten the blood fibrinolytic potential in AAA patients and contribute to the development of comorbidities. Therefore, TAFI participation in AAA pathogenesis cannot be excluded.

• 出版日期2014-4